Search

everythinglearnresearchcommunity

for

Search:↓

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Targeting FGF5 could help treat prostate cancer.

New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

Certain drugs that block specific enzymes can help treat prostate diseases.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

CT scans can find serious prostate cancer even when PSA levels are low.

CEC levels may be a useful marker for predicting prostate cancer progression.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

Provenge extends prostate cancer survival by about 4 months.

WNT10B is linked to cancer development and affects survival and disease progression in various cancers.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Androgen receptors play a key role in male development and prostate cancer, with treatments targeting androgen action.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.